Abstract: Escherichia coli respond to selective pressure of antimicrobial therapy by developing resistance through a variety of mechanisms. The purpose of this study was to characterize the genetic mechanisms of antimicrobial resistance in fecal E. coli after the routine use of 2 popular antimicrobials. Fourteen resistant E. coli isolates, representing predominant clones that emerged in healthy dogs' feces after treatment with either amoxicillin (11 E. coli isolates) or enrofloxacin (3 E. coli isolates), were tested for mutations in DNA gyrase (gyrA and gyrB) and in topoisomerase IV (parC) and for the presence of ␤-lactamases (bla TEM , bla SHV, bla PSE-1 and bla CTX-M ) and plasmid-mediated quinolone resistance (qnrA, qnrB, qnrS, and qepA), by polymerase chain reaction. Escherichia coli isolates cultured following amoxicillin therapy only expressed single-drug resistance to ␤-lactams, while the isolates cultured from dogs receiving enrofloxacin therapy expressed multidrug resistance (MDR). The use of RND efflux pump inhibitors increased the susceptibility of the 3 MDR E. coli isolates to doxycycline, chloramphenicol, enrofloxacin, and ciprofloxacin, which indicates a role of the efflux pump in the acquisition of the MDR phenotype. Amplification and sequencing of AcrAB efflux pump regulators (soxR, soxS, marR, and acrR) revealed only the presence of a single mutation in soxS in the 3 MDR isolates.
Introduction
Selective pressures resulting from previously administered antimicrobial therapy play important roles in the emergence of antimicrobial resistance. Use of antimicrobials selects for resistance not only in pathogenic bacteria but also in commensal bacteria (Sørum and Sunde 2001; Moyaert et al. 2006) . Amoxicillin, enrofloxacin (dogs), or ciprofloxacin (humans and dogs) are among the most commonly used antimicrobials in veterinary and human medicine. Amoxicillin is a semisynthetic ␤-lactam, while enrofloxacin is a synthetic fluoroquinolone (FQ) (Prescott 2006; Boothe 2012) . Resistance to both amoxicillin and FQs in companion animals and humans has been reported in several countries (Costa et al. 2004; Shaheen et al. 2009 ).
As with other FQs, bacterial resistance to enrofloxacin is principally mediated by mutations in genes encoding for the DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC) (Hooper 1999 ). However, plasmid-mediated quinolone resistance (PMQR) has become an important emerging issue (Martínez-Martínez et al. 1998) . Moreover, increases in minimum inhibitory concentration (MIC) to FQ can also be caused by mutations in genes that maintain microbial impenetrability of compounds, including quinolones. Mechanisms include increasing substrate efflux from the cell or decreasing influx through downregulation of outer membrane proteins (JellenRitter and Kern 2001) .
The polyspecificity of bacterial efflux pumps can simultaneously confer resistance to different classes of antibiotics and cause the microorganism to become multidrug resistant (MDR) (Poole 2000) . AcrAB is the main efflux pump for Escherichia coli associated with FQ resistance. A recent study suggested that acrAB overexpression is strongly correlated with FQ-associated MDR (Swick et al. 2011) . The expression of acrAB is subject to multiple levels of regulation, locally by AcrR (Ma et al. 1996) and globally by SoxS and MarA (Hirakawa et al. 2008) .
In contrast to FQ, amoxicillin resistance is most frequently mediated by ␤-lactamases (bla TEM , bla SHV , and bla CTX-M ), which inactivate the compound by hydrolyzing their lactam ring. Resistance to ␤-lactams tends to be horizontally transmitted via transferrable genetic materials, such as plasmids, integrons, or conjugative transposons (Jacoby and Bush 2005; Li et al. 2007; Cha et al. 2008) .
The purpose of this study was to characterize the genetic mechanisms of resistance to either enrofloxacin or amoxicillin in fecal E. coli of healthy dogs after the oral administration of such antimicrobials at recommended doses.
Materials and methods

Fecal E. coli isolates
The experimental E. coli isolates used in this study were collected from feces of healthy, normal dogs with no previous history of antibiotic intake. These dogs were treated orally with amoxicillin (10 mg/kg bid; n ϭ 8), enrofloxacin (5 mg/kg once daily; n ϭ 8), or no drug (control ϭ 8) for 7 days. Isolates used in this study were drawn from a larger study investigating the impact of routine antimicrobial therapy on the emergence of fecal E. coli resistance (Debavalya 2009 ). Briefly, E. coli isolates were collected from feces of healthy, normal dogs that were treated orally with amoxicillin (n ϭ 8), enrofloxacin (n ϭ 8), or no drug (n ϭ 8) for 7 days. Fecal samples were collected digitally from each dog at baseline, after 7 days of treatment and 21-28 days post-treatment. Samples were collected at the same time of each sampling day, within 1 h post-feeding. Fecal samples were processed within 2 h of collection. Serial 10-fold dilutions were prepared from 1 g of fecal sample in 0.9% sodium chloride solution. Once the appropriate dilution was identified, 0.1 mL was plated onto the surface CHROMagar E. coli agar plates (CHROMagar, Paris, France, Becton Dickinson) containing no drug, amoxicillin, or enrofloxacin at a concentration equivalent to 1 tube dilution below the resistant breakpoint MIC (MIC BP ) as determined by the Clinical Laboratory Standards Institute (CLSI) (2 g/mL agar for enrofloxacin). CHROMagar E. coli agar is a culture medium used for the detection and enumeration of E. coli based on the presence of ␤-glucuronidase enzyme. With CHROMagar E. coli, colonies of E. coli develop with an intense blue colour, while other Gram-negative bacteria appear colorless and Gram-positive bacteria are inhibited (Alonso et al. 1996) . Plates were incubated at 37°C for 18 -24 h (CLSI 2008) . Isolates were confirmed to be E. coli by screening with IMViC tests (indole, methyl red, Voges-Proskauer, and citrate) (Remel/ Thermo Fisher Scientific, Lenexa, Kansas). From each of the 3 time points for each group of dogs, 10 resistant E. coli colonies (for a total of 180 isolates) were randomly selected and their antimicrobial susceptibility and pulsed-field gel electrophoresis (PFGE) DNA fingerprints were determined. The animal use was conducted according to the guidelines of the Guide to the Care and Use of Experimental Animals. The experiment followed the ethical principles of Auburn University and was approved by the Institutional Animal Care and Use Committee of the University.
Presence of extended-spectrum b-lactamases
The E. coli isolates were tested for extended-spectrum ␤-lactamase (ESBL) production using microdilution-based Sensititre (TREK diagnostic systems, Cleveland, Ohio) with ESBL Confirmatory MIC plates (ESB1F). Presence of ESBL was based on susceptibility to 9 narrow-spectrum ␤-lactam drugs (ampicillin, cefazolin, cephalothin, cefoxitin, cefipime, cefpodoxime, ceftriaxone, cefotaxime, ceftazidime), 3 extended (broad)-spectrum ␤-lactam drugs (cefotaxime-clavulanic acid, ceftazidime-clavulanic acid, piperacillin-tazobactam) and 2 carbapenems (meropenem and imipenem), according to the manufacturer's instructions. The susceptibility status of each drug was based on comparisons of the MIC for that drug to that of the CLSI antimicrobial susceptibility standards as delineated in M100-S18 (CLSI 2008) . When the addition of the ␤-lactamase inhibitor (clavulanic acid) resulted in Ն3-fold serial dilution decrease in MIC of either antibiotic, the isolate was confirmed as an ESBL producer.
Impact of efflux pump inhibitor (EPI) on MIC
Susceptibilities to 8 antimicrobial drugs (amoxicillin, amoxicillin-clavulanic acid, cefpodoxime, amikacin, ciprofloxacin, enrofloxacin, doxycycline, and chloramphenicol) were studied by the broth microdilution method in the presence or absence of 20 mg/L concentration of Phe-Arg-␤-naphthylamide (PA␤N), in accordance with the CLSI guidelines (CLSI 2008) . Custom microtitre plates containing selected antimicrobials at increasing concentrations were purchased from Sensititre Vizion System (TREK diagnostic systems, Cleveland, Ohio, USA). For qual-ity control purposes E. coli ATCC 25922 (American Tissue Cell Culture, Manassas, Virginia, USA) was used.
Identification of putative mechanisms of resistance
The E. coli isolates were tested for mutations in genes coding for DNA gyrase (gyrA and gyrB), topoisomerase IV (parC), and transcriptional regulators of AcrAB efflux pump (soxR, soxS, marR, and acrR). The presence of plasmidencoded qnrA, qnrB, qnrS, aac(6=)-Ib-cr, and qepA was screened by polymerase chain reaction (PCR). Escherichia coli J53 strains containing pMG252, pMG298, pMG306, and pMG298 were used as qnrA-, qnrB-, qnrS-, and aac(60)-Ibcr-positive controls, respectively. Escherichia coli J7261205 (pSTVqepA) was included as a positive control for qepA (Cattoir et al. 2007; Robicsek et al. 2006; Yamane et al. 2008) . A multiplex PCR was used to screen for ␤-lactamase genes (bla TEM , bla SHV , bla PSE-1 , and bla CTX-M ). The ATCC reference strain W3110 (wild-type E. coli) was used as the control isolate. PCR amplification of these genes was performed in a Multigene Gradient Thermocycler PCR System (Labnet International Inc., Edison, New Jersey, USA). The oligonucleotide primers (Table 1) were designed using Lasergene software package (DNASTAR, Madison, Missouri, USA), based on the published sequences of the genes (GenBank accession numbers) on the National Center for Biotechnology Information web site (http://www.ncbi.nlm.nih.gov). Following amplification, PCR products were visualized in 1% agarose gel with ethidium bromide and analyzed under UV light. For detection of mutation, PCR products were purified using a QIAquick PCR purification kit (Qiagen, Inc., Valencia, California, USA) and sequenced at the DNA Core Facility of the Massachusetts General Hospital (Cambridge, Massachusetts, USA). The soxS sequence was deposited in GenBank under the accession No. GU 994539.
Conjugative transfer of resistance genes
To determine the transmissibility of the resistance determinants, conjugation was performed on the 3 MDR E. coli isolates. Horizontal transfer of antimicrobial resistance genes was investigated in all isolates with the conjugation method modified from Miller (1972) . Briefly, all isolates were grown on Luria-Bertani (LB) broth to logarithmic growth phase (OD 600 , 0.5-0.6). Conjugations were performed by mixing equal amounts of cultures of E. coli isolates and 2 different E. coli recipients: GN 3201 containing Tn5 (Tn5::Kan r ) and DH5␣ (recA -, Nal r ). CAG 5051 (Hfr, nadA-57::Tn10) E. coli containing Tn10 with tetracycline-resistant mutant was used as a positive control. The suspensions were spotted on LB plates and incubated overnight at 37°C to allow conjugation. Transconjugants were selected by plating the mated mixture on LB agar plates containing nalidixic acid, nalidixic acid ϩ enrofloxacin, and enrofloxacin at the drug concentration one tube below the MIC BP (50 g/mL kanamycin and 2 g/mL enrofloxacin, respectively). Positive control was selected on LB plates containing tetracycline at the concentration one tube below the MIC BP (8 g/mL). All of the plates were incubated at 37°C for 24 -48 h.
Results
Resistant E. coli isolates
No fecal E. coli isolates cultured in baseline samples from any of the 3 groups expressed resistance to either amoxicillin or enrofloxacin. However, within 7 days of therapy, 100% of fecal E. coli isolates cultured from dogs receiving amoxicillin therapy were found resistant against this drug. All the tested isolates were single-drug resistant (SDR), expressing a high level of resistance to ␤-lactams (MIC 90 Ն 256) only. Likewise, within 7 days of therapy, 100% of E. coli isolates cultured from dogs receiving FQ therapy expressed a high level of resistance to enrofloxacin (MIC 90 Ն32), but these isolates were all found expressing MDR, as characterized by resistance to 6 other drug classes. Thirteen PFGE DNA fingerprinting classes and 7 antibiotic-resistant phenotypes were described among the 180 isolates. From these 2 groups of dogs, a total of 14 E. coli isolates representing each PFGE class within each antibiotic-resistant phenotype were further characterized: 11 SDR E. coli isolates from amoxicillin-treated dogs and 3 MDR E. coli isolates from FQ-treated dogs. ESBL production was detected in 5 SDR E. coli isolates, with Ն3-fold dilution decreases in MICs of the third generation cephalosporins in the presence of clavulanic acid, compared with MICs of the single drugs. In contrast, no ESBL was detected in the other 6 SDR E. coli isolates or the 3 MDR E. coli isolates (Table 2) .
Changes in antimicrobial susceptibility of E. coli isolates with EPI
In the 3 MDR E. coli isolates from dogs treated with enrofloxacin, the MIC values changes were profound in the presence of EPI for selected antimicrobials. The results show that the use of a 20 mg/L concentration of PA␤N decreased the MIC of ciprofloxacin (2-fold dilution), enrofloxacin (4-fold dilution), doxycycline (from 3-to 4-fold serial dilution), and chloramphenicol (from 2-to 3-fold serial dilution) in the 3 tested MDR E. coli isolates (Fig. 1) . No change in the MIC has been detected in the 11 SDR E. coli isolates from amoxicillintreated dogs after the use of EPI. Note: MDR, multidrug resistant; ESBL, extended-spectrum ␤-lactamase. a A, ampicillin; B, carbenicillin; P, piperacillin; R, ticarcillin; L, cephalothin; C, ceftiofur; F, ciprofloxacin; E, enrofloxacin; T, tetracycline; H, chloramphenicol. 
Detection of ␤-lactamase genes
bla TEM was detected in the 6 non-ESBL-producing SDR E. coli and the 3 MDR E. coli isolates but not in the 5 ESBL-producing SDR isolates. Conversely, bla CTX-M was present only in the 5 ESBL SDR E. coli isolates. No bla SHV or bla PSE-1 was detected in any of the resistant or control isolates (Table 3) .
Mutations in quinolone resistance determining region genes
The presence of 2 mutations in gyrA at codons 83 and 87 and 2 mutations of parC at codons 80 and 84 were detected in the 3 MDR E. coli isolates. No mutations in gyrB were found in any of the isolates. For mutations in gyrA, the mutation at codon 83 was a C¡T transition in the codon TCG, resulting in the substitution of leucine for serine, while the mutation at codon 87 was a G¡A transition of codon GAC, leading to the substitution of asparagine for aspartate. For parC, a mutation at codon 80 was a G¡T transversion of codon AGC, resulting in the substitution of isoleucine for serine, and a mutation at codon 84 was a substitution of alanine for glutamate from an A¡C transversion of codon GAA (Table 3) . No mutations in quinolone resistance determining region genes were detected in the SDR E. coli isolates and the wild-type E. coli strain W3110.
Mutations in efflux pump regulators
Overexpression of the AcrAB efflux pump can result from mutations in one of several acrAB regulator genes, including soxR, which renders the protein active; soxS promoter, which initiates transcription of the soxS gene constitutively; marR, which suppresses MarA activity with the subsequent release of the inhibition exerted on marA; or acrR, which alleviates the suppression exerted on acrAB (Martin and Rosner 2002) . To address these possibilities we amplified and sequenced the genes that encode for the 4 regulators: soxR, soxS, marR, and acrR.
The 3 MDR E. coli isolates had only a single mis-sense mutation in soxS in codon 12 with G¡T transversion in codon GCA, leading to substitution of alanine with serine. No mutations were detected in soxS, soxR, marR, and acrR in any of the 11 SDR E. coli isolates or the wild-type strain (Table 3) .
Detection of PMQR
Only qnrB was detected in one of the MDR E. coli isolates. No plasmids were detected in other isolates. This suggests that PMQR did not play a role in FQ resistance in these isolates (Table 3 ).
Conjugative transfer of resistance genes
In the 5 ESBL-producing E. coli, ␤-lactam resistance was found to be transferred horizontally via conjugation. In contrast, co-transfer of the resistance traits via conjugation was not observed in any of the 6 non-ESBL-producing SDR E. coli or the 3 MDR E. coli isolates. This suggested that dissemination of resistance was not due to plasmid conjugation in these isolates.
Discussion
Emergence of MDR E. coli in response to routine antimicrobial therapy is becoming increasingly problematic in veterinary medicine (Ahmed et al. 2005 ). The dogs studied were 
a A, ampicillin; B, carbenicillin; P, piperacillin; R, ticarcillin; L, cephalothin; C, ceftiofur; F, ciprofloxacin; E, enrofloxacin; T, tetracycline; H, chloramphenicol.
healthy, with no previous history of antimicrobial administration. Prior to treatment, the fecal E. coli population was predominantly susceptible to either treatment drug, but within 7 days of therapy with either drug at doses recommended for therapeutic intervention, the E. coli population was transformed to one predominated by isolates expressing high-level resistance to the treatment drug. Further, whereas amoxicillin therapy was associated with the emergence of SDR fecal E. coli, enrofloxacin therapy was associated with the emergence of MDR fecal E. coli isolates. Five of the SDR E. coli isolates detected after amoxicillin therapy were associated with ESBL production. Previous studies have demonstrated that ␤-lactam resistance in ESBLproducing E. coli isolates is caused by plasmid-mediated CTX-M ␤-lactamases transferred horizontally during conjugation (Bonnet 2004) . In contrast, ␤-lactam resistance in either non-ESBL-producing SDR or MDR E. coli isolates is more likely to be mediated by nontransferrable TEM ␤-lactamase enzymes carried by transposons, which are then integrated into the chromosomal DNA (Poirel et al. 2008) .
De novo quinolone resistance often develops in a gradual, stepwise manner, usually from the accumulation of mutations that individually lower susceptibility by modest increments (Drlica 2003) . Our data demonstrated that the presence of 2 mutations in gyrA and 2 mutations in parC is associated with a high level of resistance to enrofloxacin (MIC Ն 256) in the resistant E. coli isolates, supporting previously published data (Webber and Piddock 2001; Liu et al. 2012) . These E. coli isolates contained the amino acid substitution of alanine for glutamate at codon 84 of parC, which is different than the previously reported mutations in E. coli. However, amino acid substitution of alanine for glutamate at codon 84 of parC has been previously reported in Enterococcus fecalis (Hooper 1999) .
The AcrAB MDR efflux pump overexpression has been shown to be associated with high-level FQ resistance in E. coli (Webber and Piddock 2001; Wang et al. 2003; Liu et al. 2012) and has been suggested to be strongly correlated with the MDR associated with FQ resistance (Swick et al. 2011; Liu et al. 2012) . Susceptibility testing of the 3 MDR E. coli isolates in the presence of the RND EPI (PA␤N) revealed a decrease in resistance to 4 antimicrobial drugs with the magnitude of resistance ranging from 2-to 4-fold (Fig. 1) . These data suggest a role for the AcrAB efflux pump in the MDR phenotype in isolates exposed to therapeutic doses of enrofloxacin. Increased activity of the AcrAB efflux pump can result from overexpression of soxS (caused by mutation in soxR) or marA (due to mutation in marR) or from mutations in acrR that inactivate the suppressor protein (Wang et al. 2003) . In this study, only a single mis-sense mutation in soxS was found that changed alanine to serine at position 12. However, there is no information is available regarding the effect of this soxS mutation on the AcrAB pump expression.
A debate that this study cannot answer is whether or not antimicrobial therapy induced isolates to acquire resistance through genetic or other changes or if the antimicrobial therapy simply exerted selection pressure, killing all but a minority population of resistant microbes that subsequently emerged as the predominant population. It is likely that both occurred; the drug induced a new minority population of resistance microbes, which subsequently emerged as the predominant population, filling the void left by those isolates killed by the drug. That induction occurred at some level is supported by the emergence of MDR isolates in response to enrofloxacin (but not amoxicillin), with isolates being characterized by both mutations in topoisomerases and increased efflux pump activity. Yet, because our techniques may not have been sensitive enough to detect the presence of a minority population containing these characteristics among a large fecal E. coli population, we cannot verify the mechanism by which these resistant populations emerged. However, regardless of the mechanism, what this study demonstrates is the rapid and complete transition of a predominantly susceptible population of E. coli to one that expressed resistance to the treatment drug; further, that the resistance that emerged with the fluorinated quinolone therapy was high level and multidrug.
Although this report was based on antimicrobial drug treatment under controlled, experimental conditions, the conditions are typical of those associated with actual clinical settings. Thus, our data suggest the rapid emergence of antimicrobialresistant mutants in clinical veterinary settings that can contribute to dissemination of drug-resistant commensal bacteria.
